Middle East And Africa Dyspepsia Drug Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
|
 CAGR |
% |
| Major Markets Players |
>中东和非洲消化不良药物市场，按类型（器质性消化不良、非溃疡性消化不良、药物引起的消化不良等）、治疗类型（药物和手术）、药物类型（品牌和通用）、处方（非处方药和处方药）、给药途径（口服和注射）、性别（男性和女性）、最终用户（医院、诊所、家庭护理机构、专科诊所、门诊手术中心、学术和政府研究机构等）、分销渠道（直接招标和零售销售）划分 - 行业趋势和预测到 2030 年。
中东和非洲消化不良药物市场分析与洞察
由于消化不良患病率不断上升以及不健康生活方式的日益盛行，中东和非洲消化不良药物市场预计在预测期内将实现增长。代谢紊乱患病率的上升也影响了市场的发展。然而，中东和非洲消化不良药物市场预计将受到消化不良药物可能产生的副作用以及人们对天然和草药疗法的日益偏爱的阻碍。人口老龄化加剧和药物审批增加预计将为市场增长带来机遇。然而，严格的法规和民众对消化不良缺乏认识预计将对市场增长构成挑战。
Data Bridge Market Research分析称，中东和非洲消化不良药物市场预计在2023年至2030年的预测期内以3.0%的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（千）、销量（个）、定价（美元） |
|
涵盖的领域 |
类型（器质性消化不良、非溃疡性消化不良、药物性消化不良等）、治疗类型（药物和手术）、药物类型（品牌药和仿制药）、处方药（非处方药和处方药）、给药途径（口服和注射）、性别（男性和女性）、最终用户（医院、诊所、家庭护理机构、专科诊所、门诊手术中心、学术和政府研究机构等）、分销渠道（直接招标和零售销售） |
|
覆盖国家 |
南非、埃及、巴林、阿拉伯联合酋长国、科威特、阿曼、沙特阿拉伯、卡塔尔以及中东和非洲其他地区 |
|
涵盖的市场参与者 |
拜耳公司、卡迪拉制药、赛诺菲、鲁宾、雅培、百利高公司、阿斯利康、宝洁、利洁时等 |
市场定义
消化不良，通常称为消化不良，是指进食后腹部疼痛和不适。它通常是潜在疾病的征兆，例如 GERD（胃食管反流病）、胆囊和溃疡病。消化不良的治疗取决于病因和严重程度。治疗潜在疾病或更换药物可以减轻消化不良。消化不良分为两大类：“器质性”和“功能性消化不良”（FD）。消化不良的器质性病因包括消化性溃疡、胃食管反流病、胃癌或食管癌、胰腺或胆道疾病、食物或药物不耐受以及其他感染性或全身性疾病。功能性消化不良（dis-PEP-see-uh）是指没有明显原因的反复胃部不适症状。功能性消化不良也称为非溃疡性消化不良。
中东和非洲消化不良药物市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
司机
- 消化不良患病率不断上升
消化不良，俗称消化不良，是一种影响中东和非洲数百万人的胃肠道疾病。这种疾病会导致不适、疼痛和上腹部饱胀感。消化不良可能是由多种因素引起的，例如进食过快、食用辛辣或油腻食物，或药物副作用。
消化不良患病率的上升是消化不良药物市场增长的关键驱动因素之一。消化不良发病率的上升可归因于生活方式、饮食习惯的改变和人口老龄化等多种因素。随着年龄的增长，人们更容易出现消化问题，包括消化不良。随着老年人口的增加，对消化不良药物的需求也随之增加。
此外，由于消化不良的发病率不断上升，各种消化系统疾病（如肠易激综合征、胃轻瘫、胃炎和消化性溃疡）也会导致消化不良。因此，消化不良和其他导致消化不良的消化系统疾病的发病率不断上升，预计将成为市场增长的驱动力。使用消化不良药物缓解消化不良症状和治疗消化不良有可能改善患者的治疗效果并减轻消化不良的负担。因此，消化不良发病率的不断上升推动了全球对消化不良药物的需求，从而增加了消化不良在人群中的发病率和患病率。
- 不健康生活方式的普及
近年来，不健康的生活方式越来越多，导致消化不良的患病率上升。不健康的生活方式，如食用大量加工食品、缺乏运动和过量饮酒都可能导致消化不良。
因此，随着人们寻求缓解消化不良症状，对消化不良药物的需求也相应增加。消化不良药物市场已经通过各种药物来满足这种需求，包括质子泵抑制剂、H2 受体拮抗剂和抗酸药。
不健康生活方式的增加可以归因于多种因素，包括饮食习惯的改变、压力水平的增加以及久坐不动的生活方式。现代生活通常以工作时间长、压力大以及快餐和其他不健康食品的易得性为特征。这些因素可能导致消化不良和其他相关疾病，如胃食管反流病 (GERD)。
总之，消化不良是一种常见疾病，可由多种因素引起，包括不健康的生活方式。不健康生活方式的增加导致消化不良患病率上升，对有效消化不良药物的需求也相应增加，这有望成为市场增长的动力。
机会
- 老龄人口不断增长
据估计，到 2050 年，65 岁及以上人口的数量预计将达到 15 亿，这表明世界人口正在迅速老龄化和老化。随着年龄的增长，人们患慢性疾病的风险更高。这包括消化不良等消化系统疾病，这些疾病可能是衰老的结果。
人口增长和老龄化为消化不良药物市场带来了巨大的扩张机会。由于越来越多的人出现消化系统问题，因此对有效治疗的需求也越来越大，这些治疗可以减轻症状的严重程度并提高他们整体的生活质量。
此外，消化不良的治疗可能需要专门针对老龄人口的需求。老年人可能患有多种慢性病，同时服用多种药物，这两者都会增加药物相互作用和副作用的可能性。因此，老年人需要既安全又有效的消化不良药物。随着年龄的增长，人们的体力和免疫力也会下降，导致包括消化不良在内的多种胃病发病率不断上升。
因此，人口老龄化导致的消化不良及其症状的增加以及人们对预防性医疗保健的偏好预计将为消化不良药物市场的增长提供机会。
克制/挑战
- 民众对消化不良缺乏认识
技能短缺已经影响到了整个国家，越来越多的人被迫等待六个月以上的牙科治疗。由于技术进步、基础设施和其他一些因素，新兴国家或发展中国家消化不良药物领域的熟练专业人员短缺。
缺乏熟练的专业人员的部分原因是成为牙科专业人员需要接受严格的教育和培训，以及竞争激烈的就业市场。此外，熟练的牙医需要更多经过正式培训、获得执照的牙科助理来帮助维持和增加获得口腔保健的机会，以操作和执行消化不良药物系统等先进的技术系统。
新兴国家缺乏熟练的专业人员，他们无法有效运用新技术。这可能会给新技术的市场发展带来挑战，因为这些国家正在推迟技术驱动的市场进步。
最新动态
- 2023年4月，赛诺菲宣布完成对Provention Bio, Inc.的收购，此次收购有助于公司拓展普药业务。
- 2022 年 7 月，ANI Pharmaceuticals, Inc. 宣布从私营生物制药公司 Oakrum Pharma, LLC 购买四个简化新药申请 (ANDA)。
中东和非洲消化不良药物市场细分
中东和非洲消化不良药物市场细分为类型、治疗类型、药物类型、处方、给药途径、性别、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
类型
- 非溃疡性消化不良
- 器质性消化不良
- 药物引起的消化不良
- 其他的
根据类型，中东和非洲消化不良药物市场分为器质性消化不良、非溃疡性消化不良、药物性消化不良等。
治疗类型
- 药物
- 外科手术
根据治疗类型，中东和非洲消化不良药物市场分为药物治疗和手术。
药物类型
- 品牌
- 通用的
根据药物类型，中东和非洲的消化不良药物市场分为仿制药和品牌药。
处方
- 无需处方药
- 处方药
根据处方，中东和非洲消化不良药物市场分为非处方药和处方药。
给药途径
- 口服
- 注射剂
根据给药途径，中东和非洲消化不良药物市场分为口服药和注射药。
性别
- 男性
- 女性
根据性别，中东和非洲消化不良药物市场分为男性和女性。
最终用户
- 医院
- 诊所
- 家庭护理设置
- 专科诊所
- 流动中心
- 学术和政府研究机构
- 其他的
根据最终用户，中东和非洲消化不良药物市场分为医院、诊所、家庭护理机构、专科诊所、门诊手术中心、学术和政府研究机构等。
分销渠道
- 直接招标
- 零售销售
根据分销渠道，中东和非洲消化不良药物市场分为直接招标和零售。
中东和非洲消化不良药物市场区域分析/见解
对中东和非洲消化不良药物市场进行分析，并根据类型、治疗类型、药物类型、处方、给药途径、性别、最终用户和分销渠道提供市场规模洞察和趋势。
本市场报告涉及的国家包括南非、埃及、巴林、阿拉伯联合酋长国、科威特、阿曼、沙特阿拉伯、卡塔尔以及中东和非洲其他地区。
由于消化不良药物领域的研究和开发不断增加，南非有望主导中东和非洲消化不良药物市场。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了中东和非洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战以及国内关税和贸易路线的影响。
竞争格局和中东和非洲消化不良药物市场份额分析
中东和非洲消化不良药物市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、中东和非洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
该市场的一些主要市场参与者包括拜耳公司、卡迪拉制药公司、赛诺菲、鲁宾公司、雅培、百利戈公司、阿斯利康、宝洁和利洁时等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END-USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA
7 INDUSTRY INSIGHTS:
8 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, REGULATION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS
9.2 RESTRAINTS
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES
9.3 OPPORTUNITIES
9.3.1 GROWING AGING POPULATION
9.3.2 RISE IN THE DRUG APPROVAL
9.4 CHALLENGES
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION
9.4.2 STRINGENT REGULATIONS
10 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE
10.1 OVERVIEW
10.2 NON-ULCER DYSPEPSIA
10.3 ORGANIC DYSPEPSIA
10.4 DRUG INDUCED DYSPEPSIA
10.5 OTHERS
11 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 DRUGS
11.2.1.1 ANTACIDS
11.2.1.1.1 PROTON PUMP INHIBITORS (PPI’S)
11.2.1.1.1.1 OMEPRAZOLE
11.2.1.1.1.2 LANSOPRAZOLE
11.2.1.1.1.3 ESOMEPRAZOLE
11.2.1.1.1.4 OTHERS
11.2.1.1.2 H2 BLOCKERS
11.2.1.1.2.1 CIMETIDINE
11.2.1.1.2.2 FAMOTIDINE
11.2.1.1.2.3 NIZATIDINE
11.2.1.1.2.4 RANITIDINE
11.2.1.1.2.5 OTHERS
11.2.1.2 GASTRIC PROKINETIC GENDERNTS
11.2.1.2.1 MOSAPRIDE CITRATE
11.2.1.2.2 METOCLOPRAMIDE
11.2.1.2.3 CISAPRIDE
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE
11.2.1.2.5 DOMPERIDONE
11.2.1.2.6 OTHERS
11.2.1.3 ANTIBIOTICS
11.2.1.3.1 REFAXIMIN
11.2.1.3.2 AMOXICILLIN
11.2.1.3.3 CLARITHROMYCIN
11.2.1.3.4 METRONIDAZOLE
11.2.1.3.5 LEVOFLOXACIN
11.2.1.3.6 TETRACYCLINE
11.2.1.3.7 OTHERS
11.2.1.4 OTHERS
11.2.2 NON- DRUGS
11.2.2.1 PROBIOTICS
11.2.2.1.1 LACTOBACILLUS
11.2.2.1.2 BIFIDOBACTERIUM
11.2.2.1.3 BACILLUS
11.2.2.1.4 STREPTOCOCCUS
11.2.2.1.5 OTHERS
11.2.2.2 PREBIOTICS
11.3 SURGERY
12 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERIC
12.3 BRANDED
13 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION
13.1 OVERVIEW
13.2 WITHOUT PRESCRIPTION DRUGS
13.3 PRESCRIPTION DRUGS
14 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 TABLETS
14.2.2 CAPSULES
14.3 INJECTABLE
15 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY GENDER
15.1 OVERVIEW
15.2 FEMALE
15.2.1 30-50 YEARS
15.2.2 MORE THAN 50 YEARS
15.2.3 AGE LESS THAN 30
15.3 MALE
15.3.1 30-50 YEARS
15.3.2 MORE THAN 50 YEARS
15.3.3 AGE LESS THAN 30
16 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.2.1 TYPE
16.2.1.1 PUBLIC
16.2.1.2 PRIVATE
16.2.2 TIER
16.2.2.1 TIER 3
16.2.2.2 TIER 2
16.2.2.3 TEIR 1
16.3 CLINICS
16.4 HOMECARE SETTINGS
16.5 SPECIALTY CLINICS
16.6 AMBULATORY CENTERS
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
16.8 OTHERS
17 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 RETAIL SALES
17.2.1 REATIL PHARMACY
17.2.2 HOSPITAL PHARMACY
17.2.3 ONLINE PHARMACY
17.3 DIRECT TENDER
18 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY REGION
18.1 MIDDLE EAST AND AFRICA
18.1.1 SOUTH AFRICA
18.1.2 EGYPT
18.1.3 BAHRAIN
18.1.4 U.A.E
18.1.5 SAUDI ARABIA
18.1.6 KUWAIT
18.1.7 OMAN
18.1.8 QATAR
18.1.9 REST OF MIDDLE EAST AND AFRICA
19 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
20 SWOT ANALYSIS
21 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS
21.1 SANOFI
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENT
21.2 LUPIN
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 MANKIND PHARMA
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 ASTRAZENECA
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENT
21.5 BAYER AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENT
21.6 ABBOTT
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ANI PHARMACEUTICALS, INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD.
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 ASTERISK LABORATORIES (I) PVT. LTD
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENT
21.1 CADILA PHARMACEUTICALS
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 COMPANY SHARE ANALYSIS
21.10.4 PRODUCT PORTFOLIO
21.10.5 RECENT DEVELOPMENT
21.11 HANMI PHARM. CO., LTD.
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENT
21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 OTSUKA PHARMACEUTICAL CO., LTD.
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 PERRIGO COMPANY PLC
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 PRESTIGE CONSUMER HEALTHCARE, INC.
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENT
21.16 PROCTER & GAMBLE
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENT
21.17 RECKITT BENCKISER.
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 REDHILL BIOPHARMA LTD
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENT
21.19 SALIX PHARMACEUTICALS OR ITS AFFILIATES (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENT
21.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 WOODWARD PHARMA
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENT
21.22 ZERIA PHARMACEUTICAL CO., LTD.
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 MIDDLE EAST AND AFRICA NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 55 MIDDLE EAST AND AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 57 MIDDLE EAST AND AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 59 MIDDLE EAST AND AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 61 MIDDLE EAST AND AFRICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 64 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 76 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 SOUTH AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 SOUTH AFRICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 SOUTH AFRICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 SOUTH AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 SOUTH AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 83 SOUTH AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 84 SOUTH AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 SOUTH AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 86 SOUTH AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 87 SOUTH AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 SOUTH AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 89 SOUTH AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 90 SOUTH AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 91 SOUTH AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 92 SOUTH AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 93 SOUTH AFRICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 SOUTH AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 SOUTH AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 96 SOUTH AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 97 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 99 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 100 SOUTH AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 101 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 102 SOUTH AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 103 SOUTH AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 104 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 105 SOUTH AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 106 SOUTH AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 107 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 108 SOUTH AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 109 EGYPT DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 110 EGYPT DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 111 EGYPT MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 EGYPT DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 EGYPT ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 EGYPT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 EGYPT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 116 EGYPT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 117 EGYPT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 EGYPT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 119 EGYPT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 120 EGYPT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 121 EGYPT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 122 EGYPT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 123 EGYPT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 EGYPT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 125 EGYPT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 126 EGYPT NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 127 EGYPT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 128 EGYPT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 129 EGYPT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 130 EGYPT DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 EGYPT DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 132 EGYPT DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 133 EGYPT ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 134 EGYPT DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 135 EGYPT FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 136 EGYPT MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 137 EGYPT DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 138 EGYPT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 EGYPT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 140 EGYPT DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 141 EGYPT RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 142 BAHRAIN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 143 BAHRAIN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 BAHRAIN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 BAHRAIN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 146 BAHRAIN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 147 BAHRAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 148 BAHRAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 149 BAHRAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 150 BAHRAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 BAHRAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 152 BAHRAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 153 BAHRAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 154 BAHRAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 155 BAHRAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 156 BAHRAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 BAHRAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 158 BAHRAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 159 BAHRAIN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 BAHRAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 BAHRAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 162 BAHRAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 163 BAHRAIN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 164 BAHRAIN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 165 BAHRAIN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 166 BAHRAIN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 167 BAHRAIN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 168 BAHRAIN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 169 BAHRAIN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 170 BAHRAIN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 171 BAHRAIN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 BAHRAIN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 173 BAHRAIN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 174 BAHRAIN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 175 U.A.E DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 U.A.E DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 U.A.E MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 U.A.E DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 179 U.A.E ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 U.A.E PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 181 U.A.E PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 182 U.A.E PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 183 U.A.E H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 184 U.A.E H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 185 U.A.E H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 186 U.A.E GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 187 U.A.E GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 188 U.A.E GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 189 U.A.E ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 U.A.E ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 191 U.A.E ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 192 U.A.E NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 U.A.E PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 194 U.A.E PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 195 U.A.E PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 196 U.A.E DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 U.A.E DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 198 U.A.E DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 199 U.A.E ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 200 U.A.E DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 201 U.A.E FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 202 U.A.E MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 203 U.A.E DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 204 U.A.E HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 205 U.A.E HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 206 U.A.E DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 207 U.A.E RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 208 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 209 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 210 SAUDI ARABIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 211 SAUDI ARABIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 SAUDI ARABIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 SAUDI ARABIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 SAUDI ARABIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 215 SAUDI ARABIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 216 SAUDI ARABIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 217 SAUDI ARABIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 218 SAUDI ARABIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 219 SAUDI ARABIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 SAUDI ARABIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 221 SAUDI ARABIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 222 SAUDI ARABIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 223 SAUDI ARABIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 224 SAUDI ARABIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 225 SAUDI ARABIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 SAUDI ARABIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 227 SAUDI ARABIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 228 SAUDI ARABIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 229 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 230 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 231 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 232 SAUDI ARABIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 233 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 234 SAUDI ARABIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 235 SAUDI ARABIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 236 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 237 SAUDI ARABIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 238 SAUDI ARABIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 239 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 240 SAUDI ARABIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 241 KUWAIT DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 242 KUWAIT DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 243 KUWAIT MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 244 KUWAIT DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 KUWAIT ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 KUWAIT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 KUWAIT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 248 KUWAIT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 249 KUWAIT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 KUWAIT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 251 KUWAIT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 252 KUWAIT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 KUWAIT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 254 KUWAIT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 255 KUWAIT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 256 KUWAIT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 257 KUWAIT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 258 KUWAIT NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 259 KUWAIT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 260 KUWAIT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 261 KUWAIT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 262 KUWAIT DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 263 KUWAIT DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 264 KUWAIT DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 265 KUWAIT ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 266 KUWAIT DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 267 KUWAIT FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 268 KUWAIT MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 269 KUWAIT DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 270 KUWAIT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 271 KUWAIT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 272 KUWAIT DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 273 KUWAIT RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 274 OMAN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 OMAN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 276 OMAN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 OMAN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 OMAN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 279 OMAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 280 OMAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 281 OMAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 282 OMAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 OMAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 284 OMAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 285 OMAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 286 OMAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 287 OMAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 288 OMAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 289 OMAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 290 OMAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 291 OMAN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 292 OMAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 293 OMAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 294 OMAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 295 OMAN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 OMAN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 297 OMAN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 298 OMAN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 299 OMAN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 300 OMAN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 301 OMAN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 302 OMAN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 303 OMAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 304 OMAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 305 OMAN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 306 OMAN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 307 QATAR DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 308 QATAR DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 309 QATAR MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 310 QATAR DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 311 QATAR ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 312 QATAR PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 313 QATAR PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 314 QATAR PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 315 QATAR H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 316 QATAR H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 317 QATAR H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 318 QATAR GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 319 QATAR GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 320 QATAR GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 321 QATAR ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 322 QATAR ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 323 QATAR ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 324 QATAR NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 325 QATAR PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 326 QATAR PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 327 QATAR PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 328 QATAR DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 329 QATAR DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 330 QATAR DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 331 QATAR ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 332 QATAR DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 333 QATAR FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 334 QATAR MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 335 QATAR DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 336 QATAR HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 337 QATAR HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 338 QATAR DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 339 QATAR RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 340 REST OF MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 8 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: MARKET END-USER COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 12 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 13 NON-ULCER DYSPEPSIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET IN 2023 & 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET
FIGURE 15 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TYPE, 2022
FIGURE 16 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 17 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 18 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , 2022
FIGURE 20 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 21 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , CAGR (2023-2030)
FIGURE 22 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2022
FIGURE 24 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)
FIGURE 25 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 26 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2022
FIGURE 28 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)
FIGURE 29 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, CAGR (2023-2030)
FIGURE 30 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 32 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 33 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 34 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY GENDER, 2022
FIGURE 36 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 37 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 38 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY END USER, 2022
FIGURE 40 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 41 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 45 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: SNAPSHOT (2022)
FIGURE 48 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2022)
FIGURE 49 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: BY TYPE (2023-2030)
FIGURE 52 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
